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Abstract
Background: Clostridium difficile associated disease (CDAD) has risen in incidence and the experience in the US
military has not been described.
Methods: We evaluated the U.S. military’s database and identified CDAD cases and demographic characteristics
among affected military personnel from 1998 to 2010.
Results: 2,423 cases were identified. CDAD incidence was 13.2 cases (95% CI: 12.7-13.7) per 100 K p-yr and
increased over study years. CA-CDAD and HA-CDAD incidence was 5.5 (95% CI: 5.2, 5.9) per 100 K p-y and 1.3
(95% CI: 1.2, 1.4) per 1,000 hospitalizations respectively. Females comprised a larger proportion of CA-CDAD than
HA-CDAD (25.5% vs. 19.3%; p < 0.001) cases as did Air Force service (29% vs. 23.4%; p < 0.01). On multivariate analysis
female gender, Coast Guard or Air Force service, and a married status was associated with CA-CDAD whereas Male
gender and Marine Corps service were associated with HA-CDAD cases.
Conclusions: CDAD has increased among military personnel, with female cases more likely to be community
associated. Gender, marital status and branch of service had the strongest association with CDAD subtype. Further work
is needed to evaluate the epidemiologic factors that have led to these increased rates in otherwise low-risk populations
and associated sequelae.
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Background
Clostridium difficile associated disease (CDAD) usually
manifests as an inflammatory, cytotoxin-mediated en-
teric disease with a wide spectrum of severity which
includes asymptomatic carriage, acute or persistent diar-
rhea, and fulminant colitis with sepsis [1]. CDAD has
increased in incidence and virulence in recent decades
[1-4]. Recurrent disease and serious morbidity have also
increased, especially among the elderly. Although the
reasons for the increase are yet to be fully elucidated,
emergence of hypervirulent strains, increased quinolone
and other antibiotic use, as well as increased awareness
and use of improved diagnostic tests have been impli-
cated [1]. Novel risk factors such as proton pump inhibi-
tor (PPI) and other medication use may also increase
risk and be associated with these trends [5-8]. No longer
a strict nosocomial illness, incidence among historically
low-risk groups such as community dwellers, pregnant
females and children represent important epidemiologic
changes which underscore a need to better characterize
the epidemiology of CDAD in younger cohorts [1].
US military personnel have full access to government
paid medical care and are recognized to be a distinct
population composed of younger and generally healthier
individuals who also have unique exposures associated
with worldwide military service. The US Department of
Defense’s Armed Forces Health Surveillance Center
(AFHSC) maintains comprehensive medical encounter
databases on all service members as part of surveillance
and public health efforts: the Defense Medical Surveil-
lance System (DMSS) and the Defense Medical Encoun-
ter Database (DMED) [9]. The objective of our study
was to use available military surveillance and medical
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encounter data to examine the epidemiology of CDAD
among active duty personnel over the last decade. A co-
hort of all diagnosed CDAD cases was constructed and
cross-sectional analysis performed.
Methods
Description of the study population
C. difficile cases were identified from among active duty
servicemembers from 1998 through 2010. Medical infor-
mation and demographic data were obtained from in-
patient and outpatient medical encounter and personnel
databases by the Defense Medical Surveillance Center,
The Armed Forces Health Surveillance Center, U.S.
Department of Defense, Silver Spring, Maryland [inclusive
dates:1998-2010; release date: March 2012]. All identifi-
able information was removed and subsequently provided
to study investigators.
The study protocol was approved by the Naval Medical
Research Center Institutional Review Board in compliance
with all applicable Federal regulations governing the pro-
tection of human subjects. Datasets were de-identified and
therefore a waiver of informed consent was granted by the
Institutional Review Board.
CDAD cases were identified by extracting individual en-
counters with ICD-9 codes for clinician diagnosed CDAD
(008.45). Setting of infection, community vs. healthcare-
associated, was defined using modified Centers of Disease
Control and Society of Healthcare Epidemiology of
America (CDC/SHEA) case definitions [10]. Commu-
nity acquired CDAD cases were individuals without in-
patient medical encounters in the twelve-week period
prior to CDAD diagnosis. Healthcare associated cases
were those diagnosed while inpatients or who had been
admitted in the twelve weeks prior to diagnosis. Clinical
and demographic characteristics were collected from all
cases.
Analysis
Demographic comparisons between CDAD cases (CA-
and HA-) were assessed using Chi-square test for
categorical variables or Wilcoxon rank-sum (Mann-
Whitney) test, as appropriate, for continuous variables
lacking a normal distribution. Incidence rates and 95%
confidence intervals were calculated using person-year
denominator data for the study years for personnel in
active duty service (CA) and hospitalizations (HA).
Multivariate analysis of cross-sectional demographic and
clinical variables associated with CA- vs. HA-CDAD was
performed using log-binomial models to estimate pre-
valence ratios (PR). Covariates associated with CA- or
HA-CDAD on univariate analyses were included in the
final models using a stepwise selection approach with
terms removed and added based on significance levels of
0.20 and 0.15 respectively.
Re-hospitalization rates were calculated by identifying
inpatient encounters for C. difficile disease which oc-
curred after 7 days and within 60 days from the original
C.difficile diagnosis.
All statistical analyses were performed using SAS v. 8.2
for Windows (SAS Institute, Cary, NC) and Stata version
12 (Stata Corp LP, College Station, TX) for Windows and
statistical significance was evaluated using an alpha = 0.05.
Results
Study cohort and baseline characteristics
A total of 2,423 active duty service members were diag-
nosed with CDAD (CA-1,018; HA-1,405) over the study
period for an overall incidence of 13.2 cases/100 K p-yr
(95% CI: 12.7,13.7). The baseline characteristics of cases
are shown in Table 1. Demographic variables closely par-
alleled the composition of the military services. Study
subjects were predominantly young (median age 30), male
(77.6%), and Caucasian (69.6%). The largest proportion of
cases (41.1%) was from the Army while less than 5% were
from the Coast Guard. Among the HA-CDAD cases diag-
nosed in outpatient clinics, 338 (24.0%) had a hospi-
talization in the 12-weeks prior to diagnosis.
Females constituted a larger proportion of the CA-
CDAD cases than HA-CDAD cases (25.5% vs. 19.3%;
p < 0.001). In terms of branch of service, the majority of
total and HA-CDAD cases came from the Army, while
the Navy and Coast Guard cases were evenly distributed
among HA- and CA-CDAD cases, and CDAD was more
common in Air Force members (29% vs. 23.5%; p < 0.001).
Among Marines, HA-CDAD occurred more commonly
(11.9% vs. 8.9%; p < 0.009). There were no significant dif-
ferences in the age, military rank or race of the CDAD
cases. The duration of follow-up (end of active duty
service) was longer for those with CA-CDAD than those
with HA-CDAD.
Incidence of Clostridium difficile
Community acquired
The overall incidence (Table 2) of CA-CDAD was 5.5
cases per 100 K p-yr (95% CI: 5.2, 5.9). Among the branch
of service, rates of CA-CDAD were highest in the Coast
Guard, Army and Air Force with lower rates in the Navy
and Marine Corps. By age category and gender, rates of
CA-CDAD were significantly higher among females (10.4
vs. 4.6 cases per 100 K p-yr) and increased significantly by
age with the highest rates seen among those over 40 with
12.0 cases per 100 K p-yr (95% CI: 10.6, 13.7).
Hospital acquired/associated
During the study period, the overall incidence of HA-
CDAD was1.3 (95% CI: 1.2, 1.4) cases per 1,000 hospital-
izations (Table 2). The Air Force and Marine Corps had
somewhat higher rates than the other services, excluding
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the Coast Guard from which detailed hospitalization rates
were unavailable. By age category, rates of HA-CDAD
were largely similar for the different age groups in our
study population without a clear increased incidence
among the oldest service members. By gender, rates of
HA-CDAD were reversed and higher for males (1.7 cases
per 1 K hospitalizations; 95% CI: 1.6, 1.8) than for females
(0.6 cases per 1 K hospitalizations; 95% CI: 0.5, 0.7).
CDAD incidence trends
CDAD incidence increased notably over the study
period. While an overall estimated incidence of less than
Table 1 Demographics and descriptive epidemiology of U.S. military (CDAD) cases (1998-2010)
All cases C. difficile cases (CDAD) n (%) total = 2,423
2,423 CA = 1,018 HA = 1,405 P value†
Age yr. (Median; IQR) 30; 24, 39 31; 25, 39 30; 23, 39 0.1529
Gender
Male 1,880 (77.6) 908 (74.5) 972 (80.7) <0.001
Female 543 (22.4) 311 (25.5) 232 (19.3)
Race
White 1,686 (69.6) 853 (70) 833 (69.2) 0.263
Black 355 (14.7) 179 (14.7) 176 (14.6)
Asian 39 (1.6) 21 (1.7) 18 (1.5)
American Indian 26 (1.1) 19 (1.6) 7 (0.6)
Hispanic 121 (5.0) 57 (4.7) 64 (5.3)
Unknown/other 196 (8.1) 90 (7.4) 106 (8.8)
Rank
O6-O10 32 (1.3) 16 (1.3) 16 (1.3) 0.900
O1-05 360 (14.9) 185 (15.2) 175 (14.5)
Warrant officer 34 (1.4) 16 (1.3) 18 (1.5)
E5-E9 1,139 (47) 581 (47.7) 558 (46.4)
E1-E4 858 (35.4) 421 (34.5) 437 (36.3)
Education
Graduate 346 (6.1) 98 (8.0) 80 (6.6) 0.001
Bachelor’s degree 675 (11.9) 164 (13.5) 153 (12.7)
Some college 591 (10.5) 174 (14.3) 129 (10.7)
High school 3,824 (67.6) 749 (61.4) 795 (66.0)
<High school 42 (0.7) 4 (0.3) 19 (1.6)
Unknown 176 (3.1) 30 (2.5) 28 (2.3)
Marital status
Married 3,160 (56) 753 (61.8) 686 (57.1) 0.006
Single never married 2,211 (39.1) 380 (31.2) 452 (37.6)
Other 273 (4.8) 83 (6.8) 63 (5.2)
Unknown 4 (0.1) 2 (0.2) 1 (0.1)
Service branch
Army 995 (41.1) 505 (41.4) 490 (40.7) 0.009
Air Force 642 (26.5) 354 (29.0) 288 (23.9)
Coast Guard 73 (3.0) 36 (3.0) 37 (3.1)
Marine corps 252 (10.4) 109 (8.9) 143 (11.9)
Navy 461 (19.0) 215 (17.6) 246 (20.4)
Follow up in days (Median duration) 677 814 608 <0.001
†Wilcoxon Rank Sum (Mann-Whitney) test used for comparison of continuous variables (Age, Duration of Follow Up); All other categorical variables evaluated with
Chi-Square test for comparison of frequencies by appropriate degrees of freedom. HA- vs. CA- comparisons.
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five cases per 100 K p-yr was seen in 1998-1999, by
2008 CDAD incidence had increased to greater than 20
cases per 100 K p-yr. The rise occurred in both CA- and
HA- cases (Figure 1). Incidence trends by gender also
revealed a rise for both men and women over the study
period (Figures 2 and 3). Branch of service contribution
to the CDAD cases changed somewhat over the study
period with a larger relative incidence for Army in the
later years (38-40% of all cases), and decreased for pro-
portions from the Air Force (data not shown).
Prior hospitalizations
The hospitalization history of all CDAD cases was evalu-
ated. Among the 1,405 HA-CDAD cases, 1,066 (76%)
were inpatients at the baseline visit and for 728 of those
(51.8% of all HA-CDAD cases) the baseline visit repre-
sented their only hospitalization on record. Among all
HA-CDAD cases, if a prior admission was present it
most often occurred in the 1 month prior to the CDAD
diagnosis. Specifically, for outpatients and inpatients at
the baseline visit, the median number of days from the
last admission was 20 days (IQR: 35, 8) and 18 days
(IQR: 38, 7) respectively (data not shown).
Multivariate analysis and prevalence ratio
Table 3 illustrates prevalence ratios associated with
demographic variables for CA-CDAD vs. HA-CDAD
after adjustment for potential confounders. In the
models, female gender and Coast Guard service was as-
sociated with CA-CDAD after adjustment for potential
confounders identified during univariate analysis.
Duration of C. difficile disease and readmissions
Among all CDAD cases, 1,451 (60%) subjects had subse-
quent CDAD-related medical encounters after the initial
visit and of these, 582 (40%) had two or more visits dur-
ing the follow up period. For a majority of both CA- and
HA-CDAD cases, the last CDAD-related code occurred
within a year after diagnosis. Of the 1,018 subjects iden-
tified as CA-CDAD cases, 519 had subsequent CDAD
Table 2 Incidence of HA and CA-Clostridium difficile infection over the study period among U.S. military personnel
(1998-2010)
CA-CDAD HA-CDAD
Category Rate (Cases per 100 K p-yr) 95% CI Rate (Cases per 1 K hospitalizations) 95% CI
Overall incidence 5.5 5.2-5.9 1.3 1.2-1.4
Branch of service
Army 6.3 5.7-6.9 1.2 1.1-1.3
Navy 4.0 3.5-4.7 1.2 1.1-1.4
Air Force 7.2 6.4-8.0 2.7 2.5-2.9
Marines 2.7 2.1-3.5 2.2 1.9-2.5
Coast Guard 8.7 6.4-11.7 Not available
Age
<20 1.8 1.3-2.7 0.5 0.4-0.7
20-24 3.8 3.3-4.3 1.1 1.0-1.3
25-29 5.6 4.9-6.4 1.4 1.2-1.6
30-34 6.1 5.3-7.1 1.7 1.5-2.0
35-39 6.4 5.5-7.5 1.7 1.5-1.9
> = 40 12.0 10.6-13.7 1.4 1.3-1.6
Race
Black 4.6 3.9-5.3 0.9 0.7-1.0
White 6.0 5.5-6.4 1.3 1.2-1.4
Native American 6.0 3.5-10.2 Not available -
Hispanic 2.3 1.7-3.2 Not available -
Asian 2.1 1.3-3.5 Not available -
Other/unk 8.0 6.2-10 0.8 0.7-1.0
Gender
Male 4.6 4.3-5.0 1.7 1.6-1.8
Female 10.4 9.2-11.7 0.6 0.5-0.7
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coded visits with the majority occurring within a month of
the original visit, and 43 (4.2%) and 64 (6.3%) having a
CDAD visit coded after 8 weeks and 4 weeks respectively.
Among the 1,405 HA-CDAD cases, 932 had subsequent
CDAD coded visits the majority of which also occurred
within a month of the original diagnosis. For HA-CDAD
cases, 68 (4.9%) and 140 (9.9%) had CDAD visits after 8 and
4 weeks, respectively, from the original diagnosis (Table 4).
In terms of re-hospitalization rates for CDAD cases.
Among all the exposed (n = 2,421), 100 (4.3%) subjects
had an inpatient encounter within 2 months for CDAD.
Ninety-six of the admissions were among cases previ-
ously classified as HA-CDAD, whereas only 4 cases were
among the previously classified as CA-CDAD (Table 4).
Discussion
In this generally healthy population of young, active-duty
US military personnel, we noted a marked rise in the inci-
dence of CDAD both in terms of hospital and community
associated disease. The overall CDAD incidence was 13.2
Figure 2 CA-CDAD burden, by gender, among US military personnel, from 1998 to 2010. Incidence is expressed per 100,000 person-years.
Figure 1 CDAD burden among US military personnel, from 1998 to 2010. Incidence of HA-CDAD is expressed per 1,000 admissions (left Y-axis);
incidence of CA-CDAD is expressed per 100,000 person-years (right Y-axis).
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cases per 100 K p-y, but was notably skewed towards
higher rates in the latter years of our study period with
10-fold and 4-fold increases in incidence for CA-CDAD
and HA-CDAD respectively. A rise in CDAD incidence
has been well documented in many populations and is as-
sociated with increased morbidity and mortality among
the elderly, infection of previously low-risk groups, and
emergence of novel risk factors such as PPI use [1-3,10-13].
A stabilization and slight rate decrease after 2009 is seen
among our HA-CDAD cases, a trend also noted in other
published reports [12,14]. Among CA-CDAD cases, and
for females, rates for the last study year were notably higher
than in prior years but care must be taken when interpret-
ing this observation. Implementation of PCR based testing
for CDAD became more prevalent among DoD medical
facilities in this period may have contributed to this obser-
vation but also our calculated rates for females may have
been subject to more variability as a minority of US military
personnel are female.
Our study was not designed to evaluate specific risk
factors associated with CDAD, yet some notable associa-
tions were observed in terms of the demographic vari-
ables evaluated. Similar to prior reports, women were
more frequently associated with the CA-CDAD cases
[11,15] with a gender specific rate markedly higher than
males in our cohort during the overall study period. Spe-
cific determinants associated with this observation cannot
be ascertained from our data but differential rates of ex-
posure to risk factors for CDAD acquisition or diagnosis
(antibiotic use, healthcare system exposure, host factors,
etc.) may be contributory. Evaluation of additional risk fac-
tors for C. difficile acquisition and development of disease
in the community setting is needed and may further
Figure 3 HA-CDAD burden, by gender, among US military personnel, from 1998 to 2010. Incidence is expressed per 1,000 hospitalizations.
Table 3 Multivariate prevalence ratios for CA-CDAD
(vs. HA-CDAD) among U.S. military personnel
Category-covariates Prevalence ratio 95% CI p-value
CA-CDAD
Female 1.28 1.15-1.42 <0.001
Married 1.16 1.04-1.29 0.0071
Air Force 1.14 1.03-1.27 0.0121
Marines 0.68 0.54-0.85 0.008
Coast Guard 1.55 1.27-1.89 <0.001
Table 4 Recurrence/relapse and re-hospitalization of
CA-CDAD vs. HA-CDAD cases
CDAD visits after index date N %
CA-CDAD (n = 1,108)
Visits after 2 wks 91 8.9
Visits after 4 wks 64 6.3
Visits after 8 wks 43 4.2
Hospitalization within 2mo. 4 0.3
HA-CDAD (n = 1,405)
Visits after 2 wks 228 16.2
Visits after 4 wks 140 9.9
Visits after 8 wks 68 4.8
Hospitalization within 2mo. 96 6.8
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validate and explain the gender specific differences in inci-
dence and prevalence which have been observed.
Similarly, in our population, racial distribution of cases
of CDAD was not uniform and those described as Black,
Caucasian and Native American had higher rates than
Hispanic and Asian groups. Published data from other
populations have differed and revealed higher rates of
CDAD and associated morbidity in persons of Caucasian
ancestry while other reports have demonstrated lower
incidence rates among Asian and other minority groups
[16]. More study is needed to further elucidate any gen-
etic or environmental factors to explain this association
in the military and other populations.
Our study found that specific CDAD rates by each
branch of military service also demonstrated some dif-
ferences. The Coast Guard, Air Force and Army shared
similar rates of CA-CDAD which were higher than those
seen in the Navy and Marine Corps. On the multivariate
models, Coast Guard or Air Force service was independ-
ently associated with CA-CDAD in our population and
suggests that in addition to basic demographics, other
factors may contribute to the different rates seen in our
service populations.
Recurrence of disease due to relapse or re-infection is
increasingly a significant management challenge. Resist-
ance to antibiotics, novel virulence determinants, and
ongoing host factors (need for broad spectrum antibiotic
therapy, immune compromise, continued exposure to
pathogen) all appear to contribute to recurrent disease
[17,18]. In our population, the majority of CA and HA
cases did not have continued visits for CDAD after 4
and 8 weeks. For those with CDAD visits after those
time points, the CDAD code was in the primary or sec-
ondary position and suggestive of relapse or re-infection.
The highest rate was among hospital associated cases for
which 6.3% had CDAD visits 8 weeks after the primary
diagnosis. Reported recurrence rates from civilian cohorts
are generally higher and range from 20-30% for both com-
munity and hospital associated cases [11,17-19]. In our
population, the low rates of CDAD specific visits after 4
and 8 weeks is notable and suggest a lower rate of relapse
or re-infection. Rates of hospitalization for CDAD in our
cohort was more common among HA-CDAD cases,
where 96 (6.8%) individuals were readmitted within
2 months with a CDAD diagnosis compared to only 4
(0.3%) of the CA-CDAD cases. Our study relied on ICD-9
codes to identify cases and poses a limitation in the ability
to distinguish recurrence and relapse but our conservative
approach makes it unlikely rates are significantly higher
than estimated.
Our study has several strengths and limitations. Access
to the large, worldwide deployed, US military population
allowed us to select and follow a large number of CDAD
cases from all services and a variety of clinical settings
but for which access to care, testing and therapy is rela-
tively uniform. This study represents the most compre-
hensive and extensive review of CDAD in the military
population and reveals the epidemiology of CDAD
largely has paralleled the trends seen in other civilian
and older populations. A main limitation of our study is
the medical encounter database nature of its design and
reliance on ICD-9 coding which may increase the risk
for misclassification. However, recently published valid-
ation studies in inpatient populations have noted a single
CDAD ICD-9CM code has a high specificity for CDAD
disease (Sp. 99.7%, Sen. 78%) and may therefore be ad-
equate tools for surveillance [20]. One concern raised by
these validation studies that may apply to our work is
the observation that there is risk for misclassifying of
CA-CDAD cases that are admitted to the hospital as
being as HA-CDAD. This is a potential bias may have
affected our results since we were unable to ensure that
cases of CDAD less than 48 hr after admission were
classified as community-acquired [13,20]. A lack of
access to specific medical procedure and medication
history precluded the ability to examine other risk fac-
tors for development of CDAD or adjustment by those
potential confounders.
Multiple factors, including period effects, may have in-
fluenced the changes in CDAD rates seen in our study.
Military specific factors, such as demographic transitions
in the military population, and the effect of operational
requirements with attendant changes in overall exposure
to combat deployments may have influenced rates in our
population during this time period but it is likely that
most of these effects would have been limited. Interest-
ingly, service in the Army and Marine Corps, younger,
an enlisted populations are more heavily involved in
combat operations, and were also more likely to be asso-
ciated with HA-CDAD. In addition, other risk factors
and secular trends, which have been documented from
other populations (i.e. quinolone and proton-pump inhibi-
tor use, availability of molecular diagnostics, increased
provider awareness, surveillance bias), may also have influ-
enced the rates and increases seen in our population.
Conclusions
In summary, in this retrospective study of the generally
younger, active duty U.S. military population, our data
documents a notable rise in incidence of both CA-CDAD
and HA-CDAD, similar to what has been seen in other
populations. Of note, we documented a female association
with CA-CDAD which persisted when controlling for ser-
vice branch and low rates of recurrence or re-infection
after the index visit. Incidence and risk factors for CDAD
among military personnel likely differ from those of the
general population, and our findings regarding the inci-
dence and patterns of CDAD need further study.
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